Gyre Therapeutics (GYRE) Change in Receivables (2013 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Receivables of -$8.6 million for Q1 2026, down 1287.4% year-over-year from $722000.0 in Q1 2025, and down 277.68% quarter-over-quarter from $4.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Change in Receivables (2013 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Receivables for 11 consecutive years, with -$8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 1287.4% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 200.64% YoY), while the FY2025 annual figure was $10.8 million, up 105.55% from the prior year.
- Change in Receivables retreated to -$8.6 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $4.8 million in Q4 2025 and bottomed at -$8.6 million in Q1 2026.
- Historically, Change in Receivables has averaged -$583000.0 across 4 years, with a median of $79000.0 in 2022.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 321.03% — and 2026, when it sank 1287.4%.
- Gyre Therapeutics' Change in Receivables stood at -$564000.0 in 2022, then surged by 303.19% to $1.1 million in 2024, then soared by 321.03% to $4.8 million in 2025, then tumbled by 277.68% to -$8.6 million in 2026.
- Business Quant data shows GYRE's Change in Receivables at -$8.6 million in Q1 2026, $4.8 million in Q4 2025, and $722000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Jun 30, 2026 | 4.47 Mn |
| Mar 31, 2026 | -8.57 Mn |
| Mar 31, 2026 | -8.57 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Mar 31, 2025 | 722,000.00 |
| Mar 31, 2025 | 722,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Jun 30, 2022 | -564,000.00 |
| Jun 30, 2022 | -564,000.00 |
| Mar 31, 2022 | -1.05 Mn |
| Mar 31, 2022 | -1.05 Mn |
| Dec 31, 2021 | 704,000.00 |
| Dec 31, 2021 | 704,000.00 |
| Sep 30, 2021 | -857,000.00 |
| Sep 30, 2021 | -857,000.00 |
| Jun 30, 2021 | 965,000.00 |
| Jun 30, 2021 | 965,000.00 |